Patient Offices
- Address
-
5 East 98th Street
7th Floor
New York, NY 10029
- Tel
- 212-241-5607
- Fax
- 212-241-3656
- Office Hours
- Monday 9:00 AM - 5:00 PM
- Tuesday 9:00 AM - 5:00 PM
- Wednesday 9:00 AM - 5:00 PM
- Thursday 9:00 AM - 5:00 PM
- Friday 9:00 AM - 5:00 PM
- Disabled Access
- Yes
Insurance Plans Accepted
- Aetna U.S. Healthcare
- Aetna U.S. Healthcare - HMO
- Blue Cross/ Blue Shield
- Blue Cross/ Blue Shield - HMO
- CenterCare, Inc.
- Cigna
- GHI HMO Select, Inc.
- Group Health Insurance, Inc.
- HealthFirst/Medicaid HMO
- HealthNet
- Medicaid
- Medicare
- MultiPlan, Inc.
- Oxford Health Plans
- Railroad Medicare
- United Healthcare
- United Healthcare - HMO
Disclaimer - Please note that the insurance accepted list may not be complete. Prior to scheduling an appointment, please contact the doctors' office to verify their participation in your plan.
Business Offices
- Address
-
5 East 98th Street, 7th Floor
New York, NY 10029
- Tel
- 212-241-7076
Michele Tagliati
ASSOCIATE PROFESSOR Neurology
Overview
| Specialty |
Neurology
|
| Clinical Interests |
Dystonia |
| |
Tremors |
| |
Movement Disorders |
| |
Huntington Disease |
| |
Gait Disorders |
| |
Tic Disorders |
| |
Botox Injection |
| |
Deep Brain Stimulation |
| |
Parkinson's Disease |
| Languages |
English |
| |
Italian |
| Gender |
Male |
| E-mail |
michele.tagliati@mssm.edu |
| Education and Training |
MD, Universita Di Roma |
| |
Residency, Neurology, Mount Sinai Hospital |
| |
Internship, Internal Medicine, Mount Sinai School of Medicine |
| |
Residency, Neurology, Universita Di Roma |
| |
Fellowship, Neuro-Aids, Mount Sinai Hospital |
| |
Fellowship, Movement Disorder, Beth Israel Medical Center |
| Awards |
2005 DMRF Presidential Award |
| |
2000 Singer/Hellman Research Award |
| |
1998 American Academy of Neurology Resident Award |
| |
1995 American Academy of Clinical Neurophysiology Fellowship |
| |
1993 Postdoctoral Research Fellowship Aaron Diamond Foundation |
| |
1990 CNR-NATO Advanced Fellowship for Research Abroad |
Dr. Michele Tagliati is Associate Professor of Neurology at Mount Sinai School of Medicine and Director of the Parkinson's Disease Center. He earned his M.D. from the University of Rome in 1986, where he also completed a residency in neurology and a fellowship in clinical neurophysiology. In 1993, Dr. Tagliati moved to New York, where he completed a second neurology residency at Mount Sinai. Upon completion of residency, Dr. Tagliati joined the movement disorders group at Beth Israel Medical Center in New York for five years. After serving as a faculty member at Albert Einstein College of Medicine, he returned to Mount Sinai to become Division Chief of Movement Disorders. Dr. Tagliati is a diplomat of the American Board of Psychiatry and Neurology.
Dr. Tagliati's contribution to the field of Movement Disorders is extensive. He is a leader in the field of deep-brain stimulation for Parkinson's disease and dystonia and currently serves as teaching faculty at the American Academy of Neurology and the Movement Disorders Society. Dr. Tagliati has published more than 50 peer-reviewed articles. He is an appointed officer of the Movement Disorders Society, an active member of the American Academy of Neurology, Scientific Advisor of the Parkinson Alliance and serves in the Scientific Board of the Bachmann-Strauss Foundation, in the Task Force for DBS in Dystonia of the Movement Disorder Society and the Guideline Project on Deep Brain Stimulation and Dystonia of the American Academy of Neurology.
Dr. Tagliati's clinical interests include primarily Parkinson's disease and related movement disorders (e.g. dystonia, tics, chorea, myoclonus). Dr. Tagliati utilizes both established pharmacological approaches and novel treatments, including deep brain stimulation and botulinum toxin injections. Cutting-edge therapeutic strategies, if clinically indicated, are also offered through the participation in available clinical trials.
Training
| Education and Training |
MD, Universita Di Roma |
| |
Residency, Neurology, Mount Sinai Hospital |
| |
Internship, Internal Medicine, Mount Sinai School of Medicine |
| |
Residency, Neurology, Universita Di Roma |
| |
Fellowship, Neuro-Aids, Mount Sinai Hospital |
| |
Fellowship, Movement Disorder, Beth Israel Medical Center |
| Board Certification |
Neurology |
Clinical Practice
| Specialty |
Neurology
|
| Clinical Interests |
Dystonia |
| |
Tremors |
| |
Movement Disorders |
| |
Huntington Disease |
| |
Gait Disorders |
| |
Tic Disorders |
| |
Botox Injection |
| |
Deep Brain Stimulation |
| |
Parkinson's Disease |
| Languages |
English |
| |
Italian |
| Board Certification |
Neurology |
Research
Deep Brain Stimulation for Movement Disorders
1. Effects of Unilateral and Bilateral DBS on mood in patients with parkinson's disease.
2. New parameters of stimulation for DBS as a Treatment of Dystonia.
3. Study Of Long-Term Outcomes And Complications of DBS for Movement Disorders.
4. Cortical-Subcortical Interaction in PD and Normal Speech with and without DBS
5. Low Frequency Deep Brain Stimulation for Gait Dysfunction in Parkinson's disease
Ongoing Clinical Trials
1. Evaluation of Bilateral Stimulation of STN using Libra Implantable Brain Stimulation System.
2. Extended Observation Study to Assess the Safety and Efficacy of Idiopathic Parkinson's Disease Patients Treated with CERE-120.
Completed Clinical Trials: 1. Multicenter, Open-Label Trial To Assess Subject Preference Of Parcopa, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared To Conventional Carbidopa/Levodopa Tablets In Subjects With Stable Parkinson's Disease.
2. Feasibility Study on the Use of a Parkinson's disease Symptoms Diary For The Planned Phase III Studies With Sarizotan (EMR 62-225).
3. A double-blind, placebo controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment associated dyskinesias (PADDY-2).
4. An international, multi-center, randomized, double-blind, parallel group, active controlled Study to evaluate onset of dyskinesias in patients taking levodopa/carbidopa and entacapone (Stalevo (r)), compared to those taking a traditional levodopa/carbidopa product [STRIDE-PD].
5. Study of the safety, tolerability and efficacy of Spheramine(R) implanted bilaterally into the postcommissural putamen of patients with advanced Parkinson's disease.
6. Randomized Start Study to Assess Rasagiline as Therapy in PD.
7. Medtronic 1629 usability study. Principal Investigator: M.Tagliati. Sponsor Medtronic. Approval dates: 4/1/07-3/31/08. Effort 5%.
8. Study of CERE-120 to Assess the Safety of Bilateral Delivery.
Publications
Tagliati M, Shils JL, Sun C, Alterman RL. Deep Brain Stimulation for Dystonia . Expert review of Medical Devices 2004; 1: 33-41.
Kedia S, Moro E, Tagliati M, Lang AE, Kumar R. Emergence of Restless Legs Syndrome (RLS) during subthalamic stimulation for Parkinson's disease . Neurology 2004; 63: 2410-2412.
Okun M, Tagliati M, Pourfar M, Fernandez H, Rodriguez RL, Alterman RL, Foote KL. Management of Referred DBS Failures: A Retrospective Analysis From Two Movement Disorders Centers. Arch Neurol 2005; 62: 1250-1255.
Alterman R, Shils J, Miravite J, Tagliati M. A lower Stimulation Frequency Can Enhance Tolerability and Efficacy of Pallidal Deep Brain Stimulation for Dystonia . Movement Disorders 2007; 22: 366-368.
Alterman RL, Tagliati M. Deep brain stimulation for torsion dystonia in children . Childs Nerv Syst 2007; 23: 1033-1040.
Alterman RL, Miravite J, Weisz D, Shils JL, Bressman S, Tagliati M. Sixty Hertz Pallidal DBS for Primary Torsion Dystonia. Neurology 2007; 69: 681-698.
Isaias IU, Alterman R, Tagliati M. Outcome Predictors for DBS in Primary Dystonia: The Role of Disease Duration. Brain 2008; 131: 1895-1902.
Tagliati M. Fine tuning gait in Parkinson's disease. Neurology 2008; 71: 76-77.
Stocchi F, Tagliati M, Olanow CW. Treatment of Levodopa-Induced Motor Complications . Movement Disorders 2008; 23(Suppl 3): S599-S612.
Halbig T, Tse W, Frisina PG, Baker BR, Hollander E, Shapiro H, Tagliati M, Olanow CW. Subthalamic Deep Brain Stimulation and Impulsivity in Parkinson's disease. Eur J Neurology 2009; In Press.
Isaias IU, Alterman R, Tagliati M. Deep Brain Stimulation for Primary Dystonia: Long-term Outcomes. Arch Neurol 2009; In press.
|
Institutes, Centers, Programs and Laboratories
The Mount Sinai Medical Center is home to an extensive array of top-notch research centers and laboratories, where scientists and researchers work to translate the rapid advances in basic science into the innovative patient care for which we are known.
Clinical Trials
Participating in Mount Sinai’s clinical trials allows you to take advantage of innovative treatments as we work together to advance the future of medicine.
|